PDS Biotechnology appoints three new pharma executives to board

PDS Biotechnology appoints three new pharma executives to board
PDS Biotechnology expands board

PDS Biotechnology has announced the appointments of John Dawson, Deborah Ramsdell, and Bruce Wendel to its Board of Directors. The three executives bring extensive experience in the pharmaceutical sector.

The company highlighted these appointments as a move to strengthen its governance and strategic leadership as it advances its oncology programs.

Earlier this year, PDS Biotechnology published Phase 2 trial results for its HPV16 immunotherapy and shifted its focus to PDS0301 in metastatic colorectal cancer, according to a company update. The firm is also scheduled to present new PDS0301 clinical data in advanced liver-related cancers at an upcoming virtual KOL event, as announced in previous disclosures. These recent developments align with the company’s initiatives to advance its oncology pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.